Skip to main content
Download PDF

In vitro and in vivo effects of traditional Chinese medicine formula T33 in human breast cancer cells

BMC Complementary and Alternative Medicine volume 19, Article number: 211 (2019) Cite this article

Abstract

Background

Breast cancer is the leading cause of cancer-related death in women worldwide. Although traditional Chinese medicine (TCM) is commonly used by patients with breast cancer, little is known about TCM prescriptions for breast cancer. This study investigated the effects of a new TCM formula, T33, comprising Radix Kansui, Rheum rhabarbarum, Paeonia lactiflora, Jiangbanxia, and Zhigancao on breast cancer cells in vitro and in vivo.

Methods

To evaluate the effects of T33 on human breast cancer, HMEpiC, MDA-MB231 and MCF-7 cells were treated with different concentrations of T33 and then analyzed using MTT and Transwell migration assays. To elucidate the involvement of autophagy in the T33-induced death of MDA-MB231 and MCF-7 cells, immunofluorescence staining with LC3-II-specific antibodies was performed. Tumor xenografts were generated by subcutaneously injecting either MDA-MB231 or MCF-7 cells into BALB/c nude mice to determine the effects of T33 on these cell lines in vivo.

Results

The experimental results revealed that 0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33 significantly inhibited the proliferation and invasion of MDA-MB231 and MCF-7 cells. Moreover, significant autophagy was observed in MDA-MB231 and MCF-7 cells in the presence of 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33. An animal study further revealed that both low (200 mg/kg) and high (600 mg/kg) doses of T33 inhibited the proliferation of xenografted breast cancer cells in BALB/c nude mice.

Conclusion

These findings demonstrate for the first time that T33 has potential in the treatment of breast cancer owing to its antiproliferative effects and induction of autophagy.

Peer Review reports

Background

Breast cancer is among the top five most frequently diagnosed cancers globally and the most threatening health problem for women in terms of both incidence and mortality in nearly all countries [1, 2]. Mounting evidence reveals that breast cancer is an important life-threatening malignancy for women in most Asian countries, and its incidence more rapidly is increasing in Asian countries than in Western countries [3, 4]. Various approaches for managing breast cancer have been utilized, including surgery, radiation therapy, endocrine therapy and chemotherapy [5]. Although surgical resection combined with radiotherapy and/or chemotherapy is widely used for breast cancer treatment, metastasis and recurrence contribute to the high mortality associated with breast cancer [6]. Chemotherapy for breast cancer is frequently accompanied by side effects and drug resistance, resulting in therapeutic failure in clinical practice [7]. Therefore, alternative treatments are urgently required to improve the efficacy of breast cancer treatment.

The use of traditional Chinese medicine (TCM) to treat cancer has been recorded in Chinese medical texts and publications for more than two millennia [8,9,10]. Indeed, TCM is widely used by nearly half of cancer patients and by an even greater proportion (63 to 83%) of patients with breast cancer [11,12,13,14]. Notably, the use of TCM in Western countries is increasing, ranging from 9 to 69% [15, 16]. According to studies in Australia, 65% of cancer patients use some form of CAM, with TCM usage by as high as 36% of patients and breast cancer survivors being among the most frequent users [17,18,19,20]. According to a population-based study, Hedyotis diffusa plus Scutellaria barbata is the most common duplex medicine (10.9%) used for the core treatment of breast cancer [21]. Another study reported that the extract of Astragalus membranaceus (AM) induces apoptosis in MCF-7, SK-BR-3 and MDA-MB-231 cells through the PI3K/AKT/mTOR signaling pathway [22]. These in vitro studies focused on the use of TCM to treat breast cancer.

Traditional Chinese medicine (TCM) has become increasingly popular because of its reputed safety and clinical efficacy for breast cancer, especially its synergistic effects and reduced side effects and toxicity. The T33 formula mainly consists of Gan Sui Ban Xia Tang (Radix Kansui, Paeonia lactiflora, Pinelliae Rhizoma Praeparatum and Glycyrrhizae Radix et Rhizoma) and Rheum rhabarbarum. Gan Sui Ban Xia Tang is a traditionally Chinese decoction originally used in the treatment of patients with hidden pulse, spontaneous diarrhea and malignant pleural effusion [23, 24]. Notably, various studies have indicated that the ingredients of Gan Sui Ban Xia Tang, especially Paeonia lactiflora Pall. and Glycyrrhizae Radix et Rhizoma, have anti-breast cancer activities [25, 26]. Paeonia lactiflora Pall. has been demonstrated to inhibit HIF-1α expression in MDA-MB-231 breast cancer cells through PI3K/Akt signaling [25]. Another study reported that isoliquiritigenin in Glycyrrhizae Radix et Rhizoma inhibits the ability of M2 macrophages to promote breast cancer cell migration [26]. Other studies also reported that methyl esters and derivatives of Radix Kansui induce apoptosis in human gastric cancer cells (SGC-7901) [27], and Pinelliae Rhizoma has been used to treat cancer, cough and phlegm [28]. Moreover, N-oxalylglycine (NOG) is a natural product in Rheum rhabarbarum and is now being developed for cancer therapy [29, 30]. These findings suggest that each ingredient of T33 has antitumor activity, including anti-breast cancer activity. Therefore, the current study involved further experiments on T33 in breast cancer cells in vitro and in vivo and demonstrated the anti-breast cancer activity of T33.

Methods

Preparation of traditional Chinese medicine T33

T33 was provided by Dejeu Herbaltech Co, Ltd., Taichung, Taiwan. The main components of this prescription are Radix Kansui, Rheum rhabarbarum, Paeonia lactiflora, Jiangbanxia (pinelliae rhizoma praeparatum), and Zhigancao (glycyrrhizae radix et rhizoma). Briefly, 3 g Radix Kansui, 2 g Rheum rhabarbarum, 12 g Paeonia lactiflora, 6 g Jiangbanxia and 9 g Zhigancao in 1000 mL reverse osmosis water is simmered to 250 mL to obtain an extract. Undissolved materials were separated out by filtration through Whatman filter paper and subsequently 0.22 μm membrane filter paper under sterile condition. T33 was then are obtained by extraction by freeze drying. Two gram of T33 is dissolved in PBS to the desired concentration.

Cell culture and treatments

Two human breast adenocarcinoma cell lines, including MDA-MB231 (ATCC® HTB-26™) and MCF-7 (ATCC® HTB22™), and one normal control cell line, human mammary epithelial cells, HMEpiC, were obtained from ATCC (Rockville, MD, USA) and ScienCell (CA, USA). The MDA-MB231, MCF-7 and HMEpiC cells were cultured with Leibovitz’s L-15 Medium (Cat No 30–2008), Eagle’s Minimum Essential Medium (Cat No 30–2003) and Mammary Epithelial Cell Medium (MEpiCM, Cat No 7611) in a 5% CO2 humidified incubator at 37 °C.

MTT assay

MTT assay was performed as described in previous studies [31, 32]. Each well of a 96-well culture plate was seeded with 5 × 103 cells and cultured overnight. The cells were then cultured with fresh medium containing different doses of T33 for another 1 or 2 day, respectively. For detecting cell viability, 0.2 mL MTT was added to each well of culture plate for another 2-h incubation. After dissolving the crystal with 0.2 mL DMSO, the optical density (O.D.) of the supernatant was measured at 570 nm with an ELISA reader. The ratio of cell survival was revealed as the O.D. value of the sample relative to the control.

Trans-well migration assay

Cell migration of MDA-MB231 and MCF-7 cells was detected with a 24-well Matrigel™ Invasion inserts (8 μm pore size; BD Biosciences, Franklin Lakes, NJ, USA) as described elsewhere [32]. Serum-free medium containing different concentrations of T33 and 2 × 104 cells were loaded into the upper chamber whereas the 10% fetal bovine serum (FBS)-containing medium was loaded into the lower chamber. After 24 h incubation, 10% neutral-buffered formalin was used to fix the migrated cells on the lower surface of the membrane and the migrated cells were then stained with 0.5% crystal violet for 15 min. The stained cells were then counted in five randomly selected microscopic fields at 200× magnification per filter.

Immunoblotting

Antibodies against LC3-II (NB100–2220, LC3B Antibody Novus Biologicals) and β-Actin (Upstates, Charlottesville, Virginia, USA) were used for detecting the appearance of autophagy. First, the NC membrane was incubated with the antibodies in PBS with 2.5% BSA for 3 h. After washing with PBS for 3 times, the horseradish peroxidase (HRP)-conjugated antibody was added and incubated for another hour. Finally, the antigen-antibody complexes were detected with Immobilion Western HRP Chemiluminescent Substrate (Millipore, USA) and a densitometry apparatus (Appraise, Beckman-Coulter, Brea, California, USA) was used to quantify the blots.

Immunofluorescence staining

A LC3B Antibody Kit (Invitrogen Cat No L10382) was adopted for autophagy detection. First, MDA-MB231 and MCF-7 cells were cultured on coverslips and fixed in 4% paraformaldehyde. The coverslips were then permeabilized with 0.3% Triton X-100 for 5 min and incubated in blocking solution at room temperature, followed by hybridizing with anti-LC3-II antibodies (Invitrogen Catalog no. L10382). After the incubation with Alexa Fluor® conjugated secondary antibodies (Invitrogen Cat No L10382), ProLong™ Gold Antifade Mountant with DAPI (Thermo Fisher Scientific Inc., MA, USA) was used to mount the coverslips. The cells were observed under a ZEISS AXioskop2 fluorescence microscope (Carl Zeiss Microscopy, LLC, NY, USA).

Animals and tumor xenografts

Animals and tumor xenografts experiments were performed as described in previous studies [31,32,33]. This study was approved by the Institutional Animal Care and Use Committee at Chung Shan Medical University (IACUC approval number: 1743) and follows the principles of laboratory animal care (NIH publications). Thirty female athymic nude mice (5-week old) were obtained from the National Center for Experimental Animals (National Science Council, Taiwan) and kept in a specific pathogen-free (SPF) facility. These mice have free access to diet and water for 7 days to acclimate the environment. Tumor xenografts were generated by subcutaneously injecting either MDA-MB231 (5 × 106 cells in 100 μL sterilized PBS) or MCF-7 cells (5 × 106 cells in 100 μL sterilized PBS) into the second mammary fat pad of nude mice to determine the effects of T33 in vivo. When the tumor size reached nearly 50 mm3, the animals were randomly assigned to 3 groups (n = 5 for each group), including control, low-dose and high-dose groups, respectively. The mice from control group, low-dose group and high-dose group were daily treated with 1 X PBS, 200 mg/kg T33 and 600 mg/kg T33, respectively, by oral gavage for 5 weeks. Tumor volumes of mice from all groups were measured and calculated weekly. No adverse events were observed during this study. At end point, the mice were sacrificed with CO2 asphyxiation and the tumor sizes were measured.

Statistics

The sample size was calculated with free sample size calculating software G*Power version 3.1.9.2 (Franz, Universitat Kiel). With a power of 80%, 0·05 level of statistical significance and effect size of 0·8, the sample size for each test was calculated to be 5. All data presentation and statistics were generated using GraphPad Prism 5 software (GraphPad Software, Inc.). The comparisons in the tumor sizes among groups were performed by one-way ANOVA with Bonferroni post-hoc tests followed by Student’s unpaired two-tailed t-test. For in vitro experiments, including MTT assay, Trans-well migration assay and Immunoblotting, two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons was performed to calculate effects of cell type and different treatment. A statistically significant difference was exhibited as P < 0.05. All values are revealed as mean ± SEM.

Results

T33 reduces the proliferative and invasive capacities of MDA-MB231 and MCF-7 cells in vitro

To evaluate the effects of T33 on human breast cancer, HMEpiC, MDA-MB231 and MCF-7 cells were treated with different concentrations of T33 and then analyzed using MTT and Transwell migration assays. Significantly reduced survival rates of both MDA-MB231 (approximately − 12.5% ~ − 16.3%) and MCF-7 cells (approximately − 18.8% ~ − 43.5%) compared to HMEpiC cells were observed in the presence of 0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33 at 24 h (Fig. 1a). Similar results were obtained for both MDA-MB231 (approximately − 13% ~ − 51%) and MCF-7 cells (approximately − 16.5% ~ − 25.3%) after 48 h of treatment with different concentrations of T33 (Fig. 1b). As revealed by the Transwell invasion chamber assay, a significantly reduced percentage of MDA-MB231 (approximately − 38.3% ~ − 98%) and MCF-7 cells (approximately − 20.8% ~ − 100%) invaded in the presence of 0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33 (Fig. 2). Notably, significantly lower cell survival and cell invasion were detected in MCF-7 cells than in MDA-MB231 cells in the presence of 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33 at 48 h (Fig. 2).

Fig. 1
figure1

Effects of T33 on viability of HMEpiC, MDA-MB231 and MCF-7 cells. Relative cell survival rates of HMEpiC, MDA-MB231 and MCF-7 cells after treatment with different concentrations of T33 for a 24 and b 48 h. Similar results were observed in triplicate experiments. The superscripts 1, 2, 3, 4 and 5 refer to significant differences (P < 0.05) from the HMEpiC control, MDA-MB231 control, HMEpiC, MCF-7 control and MDA-MB231, respectively

Full size image
Fig. 2
figure2

Effects of T33 on the invasive capacity of MDA-MB231 and MCF-7 cells. Transwell migration assay was performed in MDA-MB231 and MCF-7 cells after treatment with different concentrations of T33 for 24 h. Similar results were observed in triplicate experiments. The superscripts 1, 2, and 3 refer to significant differences (P < 0.05) from the MDA-MB231 control, MCF-7 control and MDA-MB231, respectively

Full size image

T33 induces autophagy in MDA-MB231 and MCF-7 cells in vitro

To elucidate the involvement of autophagy in the T33-induced death of MDA-MB231 and MCF-7 cells, immunofluorescence staining with LC3-II-specific antibodies was performed. Apparent protein expression of LC3-II was observed in both MDA-MB231 and MCF-7 cells that had been treated with different concentrations of T33 (Fig. 3). The dose-dependent effect of T33 on LC3-II expression was verified by immunoblotting (Fig. 4a). Significantly higher ratios of LC3-II/β-actin were detected in MDA-MB231 cells treated with 2.5 mg/mL (0.43 ± 0.09), 5 mg/mL (0.69 ± 0.14) or 10 mg/mL (0.89 ± 0.14) T33 than in those treated with the control (0.24 ± 0.07) (Fig. 4b). Significantly higher ratios of LC3-II/β-actin were also detected in MCF-7 cells treated with 0.5 mg/mL (0.57 ± 0.10), 2.5 mg/mL (1.00 ± 0.16), 5 mg/mL (1.10 ± 0.36) or 10 mg/mL (1.73 ± 0.28) T33 than in those treated with the control (0.42 ± 0.09) (Fig. 4b). Notably, significantly higher amounts of LC3-II were detected in MCF-7 cells than in MDA-MB231 cells in the presence of 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL or 10 mg/mL T33 for 48 h (Fig. 4b).

Fig. 3
figure3

Detection of autophagy in MDA-MB231 and MCF-7 cells. Representative images of immunofluorescence staining of LC3-II specific antibodies in MDA-MB231 and MCF-7 cells that were treated with different concentrations of T33 for 48 h and reacted with DAPI (left panel) and antibodies against LC3-II (middle panel). Right panel indicates the merged images of DAPI and LC3-II. An arrow indicates the expression of LC3-II. Similar results were observed in triplicate experiments. Scale bars = 20 μm

Full size image
Fig. 4
figure4

Expression of autophagy-related proteins. MDA-MB231 and MCF-7 cells were treated with different concentrations of T33 for 48 h and a expressions of LC3-I and LC3-II proteins in MDA-MB231 and MCF-7 cells were detected with immunoblotting. Ratios of LC3-II/β-Actin in b MDA-MB231 and MCF-7 cells are shown. Similar results were observed in triplicate experiments. The superscripts 1, 2, and 3 refer to significant differences (P < 0.05) from the MDA-MB231 control, MCF-7 control and MDA-MB231, respectively

Full size image

T33 suppresses the growth of xenografted MDA-MB231 and MCF-7 cells in vivo

To determine the effects of T33 in vivo, tumor xenografts were generated by subcutaneously injecting either MDA-MB231 (5 × 106 in 100 μL PBS) or MCF-7 cells (5 × 106 in 100 μL PBS) into BALB/c nude mice. When the size of the tumor reached nearly 50 mm3, the mice were orally gavaged with 0.5 mL PBS, 200 mg/kg T33 in 0.5 mL PBS and 600 mg/kg T33 in 0.5 mL PBS daily, respectively. Significantly lower mean MDA-MB231 tumor volumes were detected in mice that had been treated by oral gavage with 200 mg/kg (177.4 ± 19.4 mm3) or 600 mg/kg T33 (46.6 ± 9.8 mm3) than in those treated with the control (324.6 ± 61.4 mm3) (Fig. 5a). Similar results were obtained for mice that had been injected with MCF-7 cells; significantly lower mean tumor volumes were detected in mice that had been treated with 200 mg/kg (326.1 ± 48.1 mm3) or 600 mg/kg T33 (43.2 ± 10.8 mm3) than in those treated with the control (678.1 ± 102.7 mm3) (Fig. 5b). The lower panels in Fig. 5a and b show representative images of xenograft tumors excised at the experimental endpoint from BALB/c nude mice that had been treated with PBS, 200 mg/kg T33 or 600 mg/kg T33.

Fig. 5
figure5

Effects of T33 on growth of MDA-MB231 and MCF-7 cells in nude mice. After injection of a MDA-MB231 or b MCF-7 cells into second mammary fat pad of athymic BALB/c nude mice, the mice were administered 200 mg/kg and 600 mg/kg T33 daily, respectively, by oral gavage with PBS. Tumor volumes were measured weekly with a caliper and average weight of tumors from mice was analyzed. Representative images of retrieved xenograft tumors at endpoint are shown in the lower panel. The superscripts 1 and 2 refer to significant differences (P < 0.05) from the control (0 mg/kg) and 200 mg/kg, respectively

Full size image

Discussion

The use of traditional Chinese medicine (TCM) for cancer treatment has a long history, but current knowledge of TCM prescriptions for breast cancer is poor [34]. This study reports the inhibitory effects of a new TCM formula, T33, comprising Radix Kansui, Rheum rhabarbarum, Paeonia lactiflora, Jiangbanxia (Pinelliae Rhizoma Praeparatum), and Zhigancao (Glycyrrhizae Radix et Rhizoma) on breast cancer cells. The experimental results revealed that T33 significantly inhibited the growth and invasion of MDA-MB231 and MCF-7 cells (Figs. 1 and 2) and induced autophagy in these cells (Figs. 3 and 4). The in vivo study further indicated that T33 suppresses the proliferation of xenografted MDA-MB231 and MCF-7 cells in BALB/c nude mice (Fig. 5). These findings demonstrate that T33 may have potential in breast cancer treatment by causing autophagy and inhibiting proliferation and invasion.

Traditional Chinese medicinal herbs are used worldwide. Radix Kansui (RK) is a member of the family Euphorbiaceae, and the root extract of RK has been demonstrated to have various biological activities, including antiviral, antiproliferative, and immunomodulatory effects [35]. The major constituents extracted from RK can remove virus-infected cells by activating lymphocytes and significantly inhibit the growth of embryonic cells and intestinal epithelioid cells [36, 37]. Evidence has also shown that RK extract ameliorates the symptoms of psoriasis by inhibiting Th17 differentiation and activating dendritic cells [36]. Notably, methyl esters and derivatives of RK cause cell cycle arrest and apoptosis in human gastric cancer cells (SGC-7901) [27]. Rheum rhabarbarum (Rr) has long been used in Eastern countries for the treatment of inflammation. The bioactive component of Rr, aloe-emodin, exerts anti-inflammatory activity by reducing the production of proinflammatory cytokines in LPS-induced RAW264.7 macrophages [38]. N-Oxalylglycine (NOG) exists in Rr leaves and is identified as an inhibitor of 2OG oxygenase that involves in the hypoxic response and chromatin modification in animals; thus, it has attracted extensive interest in the field of cancer research [30]. The major constituent of Paeonia lactiflora (Pl), paeoniflorin, is a monoterpene glycoside extracted from the roots of Pl that has been extensively used in the treatment of various diseases, including hyperlipidemia and diabetes-associated cognitive dysfunction [39, 40]. Paeoniflorin is known to inhibit the proliferation and invasion of various cancer cells, including pancreatic cancer, prostate cancer, hepatoma, bladder cancer, and lung cancer cells [41,42,43,44]. Pinelliae Rhizoma Praeparatum (RP) and Glycyrrhizae Radix et Rhizome (GR) have also been used to treat various diseases, including hepatic disorders and chemotherapy-induced nausea and vomiting in combination regimens [45]. Although various constituents of T33 exhibit anticancer activity, the effect of this TCM formula on breast cancer is still unclear. Notably, the current study reveals that T33 significantly inhibits the growth (Fig. 1), reduces the invasive ability (Fig. 2), and induces autophagic cell death (Figs. 3, 4 and 5) in both MDA-MB231 and MCF-7 cells, suggesting the potential of T33 in breast cancer therapy. Anyway, further investigations are required to confirm the exact mechanism.

As a basic cellular process, autophagy plays an essential role under physiological and pathophysiological conditions in coping with cellular stress [46]. Briefly, cellular material is engulfed in autophagosomes, which fuse with lysosomes to enable subsequent degradation via lysosomal enzymes [47]. Recently, compelling evidence has revealed an effective therapeutic strategy for treating cancer that involves suppressing cancer metastasis and promoting cancer cell death [48, 49]. In particular, this study is the first to demonstrate that T33 induces significant autophagy in MDA-MB231 and MCF-7 cells and inhibits the proliferation of xenografted MDA-MB231 and MCF-7 cells in nude mice (Fig. 5). Since malignant transformation leads to changes in lysosomal structure and function [50], T33 increases the sensitivity of cancer cells to lysosomal destabilization, leading to autophagic cell death (ACD). Because autophagy is a double-edged sword with both cytoprotective and cytotoxic effects, a better understanding of the impact of T33 on autophagy regulatory mechanisms is clearly needed.

Expressions of estrogen receptor 1 (ESR1), progesterone receptor (PGR), and human epidermal growth factor receptor type 2 (HER2) are deficient in triple-negative breast cancer (TNBC) breast cancer. The patients with TNBC have high recurrence and the majority of deaths for TNBC patients occur within the first 5 years after diagnosis [31, 51]. Due to the lack of specific therapeutic targets, chemotherapy is the major method for TNBC treatment. Unfortunately, chemotherapeutics have been found to have inverse effect in TNBC patients by enriching cancer stem cells (CSCs) [52]. Therefore, alternative treatments for TNBC are strongly required. Notably, evidence has demonstrated that malignant transformation causes lysosomal compartment alterations and makes cancer cells more sensitive to lysosome-targeting agents by promoting autophagy [50, 53, 54]. These findings offer a possibility of tumor-specific eradication. The current study reveals that T33 can significantly inhibit the growth of MDA-MB231 cells, a triple-negative breast cancer line, both in vitro and in vivo by inducing autophagy (Figs. 1, 2, 3, 4 and 5), which provides a possible therapeutic solution for TNBC. However, a more detailed investigation is required to identify the mechanism of T33-induced autophagy in triple-negative breast cancer cells to improve the treatment of breast cancer.

Most breast cancer patients have luminal breast cancer, which is positive for ESR1 and/or HER2, whereas other patients with TNBC, which is negative in expression of ESR1, PGR and HER2 (ER−/PR−/HER2-) [55]. These findings provide reasonable rationale that distinct mechanisms are involved in the etiology of different subsets of breast cancer. Various signaling pathways, such as the PI3K/Akt [25], STAT [56], intrinsic apoptosis [57, 58], Hedgehog [59] and Akt/mTOR signaling pathways [31, 60], are linked to the pathogenesis of different breast cancer subsets and considered as potential targets for breast cancer therapy. The current study demonstrates that T33 induces both MCF-7 and MDA-MB231 cell death by inducing autophagy (Figs. 3 and 4). However, MCF-7 cells underwent autophagic cell death at a significantly higher rate than MDA-MB231 cells in the presence of T33 (Figs. 1, 2, 3 and 4). This finding indicates that MCF-7 cells are more sensitive than MDA-MB231 cells to T33 and suggests the involvement of different mechanisms in MCF-7 and MDA-MB231 cells that respond to T33 treatment. Since the etiology of breast cancer may be one of the most complicated of all cancers [61], more investigations are needed to verify the precise mechanism of T33, as well as potential differences in this mechanism, in luminal breast cancer and TNBC.

Conclusions

Although therapeutic methods such as surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy are significantly improving, a growing number of cancer patients use TCM formulas as adjuvant therapy because of their multi-target and synergistic effects [62]. As shown in Fig. 6, this study is the first to report that T33 induces significant autophagy and inhibits the growth and invasion of breast cancer cells, including TNBC cells, suggesting an alternative remedy for breast cancer therapy.

Fig. 6
figure6

In vitro and in vivo effects of T33 on breast cancer cells. T33 significantly inhibits the proliferation and invasive ability of MDA-MB231 and MCF-7 cells in vitro by inducing autophagy. T33 also significantly suppresses the growth of xenografted MDA-MB231 and MCF-7 cells in vivo. TNBC: triple-negative breast cancer

Full size image

Availability of data and materials

All data of this study is included in this article.

Abbreviations

AM:

Astragalus membranaceus

CAM:

Complementary and alternative medicine

Pl:

Paeonia lactiflora

RK :

Radix Kansui

Rr:

Rheum rhabarbarum

TCM:

Traditional Chinese medicine

TNBC:

Triple-negative breast cancer

References

  1. 1.

    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  Google Scholar 

  2. 2.

    Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. Int J Cancer. 2016;139:2436–46.

    CAS  Article  Google Scholar 

  3. 3.

    Yip CH. Breast cancer in Asia. Methods Mol Biol. 2009;471:51–64.

    Article  Google Scholar 

  4. 4.

    Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol. 2012;13:790–801.

    Article  Google Scholar 

  5. 5.

    Lukaszewicz K, Wtorek J, Bujnowski A, Skokowski J. Monitoring of breast tissue thermo-ablation by means of impedance measurements. J Phys Conf Ser. 2010;224:012136.

    Article  Google Scholar 

  6. 6.

    Dickler A, Ivanov O, Francescatti D. Intraoperative radiation therapy in the treatment of early-stage breast cancer utilizing xoft axxent electronic brachytherapy. World J Surg Oncol. 2009;7:24–9.

    Article  Google Scholar 

  7. 7.

    Kruzliak P, Stefanicka P, Büsselberg D, Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P, Opatrilova R. Chemotherapeutic agents for the treatment of metastatic breast cancer: an update. Biomed Pharmacother. 2018;101:458–77.

    Article  Google Scholar 

  8. 8.

    Sun Y. The role of Chinese medicine in clinical oncology. Chin J Integr Med. 2014;20:3–10.

    CAS  Article  Google Scholar 

  9. 9.

    He QH, Li YQ, Zhou X. Traditional Chinese medicine promotes the development of andrology. Zhonghua Nan Ke Xue. 2016;22:675–9.

    PubMed  Google Scholar 

  10. 10.

    Liang HF, Yang YH, Chen PC, Kuo HC, Chang CH, Wang YH, Wu KM. Prescription patterns of traditional Chinese medicine amongst Taiwanese children: a population-based cohort study. BMC Complement Altern Med. 2018;18:191.

    Article  Google Scholar 

  11. 11.

    DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. J Clin Oncol. 2002;20(18suppl):34S–8S.

    PubMed  Google Scholar 

  12. 12.

    Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, Bruyns I, Fernadez-Ortega P, Panteli V, Margulies A, Gudmundsdottir G, Milovics L, Ozden G, Platin N, Patiraki E. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 2006;14:260–7.

    Article  Google Scholar 

  13. 13.

    Huebner J, Muenstedt K, Prott FJ, Stoll C, Micke O, Buentzel J, Muecke R, Senf B. Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care. 2014;9:60–3.

    Article  Google Scholar 

  14. 14.

    Sun X, Zhang X, Nian JY, Guo J, Yin Y, Zhang GL, Yu MW, Zhang Y, Wang XM, Yang GW, Yang L, Cheng PY, Li JP. Chinese herbal medicine as adjunctive therapy to chemotherapy for breast cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2016;2016:3281968.

    PubMed  PubMed Central  Google Scholar 

  15. 15.

    Harris P, Rees R. The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complement Ther Med. 2000;8:88–96.

    CAS  Article  Google Scholar 

  16. 16.

    Ernst E. Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ. 2000;78:252–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Cui Y, Shu XO, Gao YT, Wen WQ, Ruan ZX, Jin F, Zheng W. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat. 2004;85:263–70.

    Article  Google Scholar 

  18. 18.

    Adams M, Jewell AP. The use of complementary and alternative medicine by cancer patients. Int Semin Surg Oncol. 2007;4:10.

    Article  Google Scholar 

  19. 19.

    Boon HS, Olatunde F, Zick SM. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health. 2007;7:4.

    Article  Google Scholar 

  20. 20.

    Cooke M, Mitchell M, Tiralongo E, Murfield J. Complementary and alternative medicine and critical care nurses: a survey of knowledge and practices in Australia. Aust Crit Care. 2012;25:213–23.

    Article  Google Scholar 

  21. 21.

    Yeh YC, Chen HY, Yang SH, Lin YH, Chiu JH, Lin YH, Chen JL. Hedyotis diffusa combined with Scutellaria barbata are the core treatment of Chinese herbal medicine used for breast cancer patients: a population-based study. Evid Based Complement Alternat Med. 2014;2014:202378.

    PubMed  PubMed Central  Google Scholar 

  22. 22.

    Zhou R, Chen H, Chen J, Chen X, Wen Y, Xu L. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med. 2018;18:83.

    Article  Google Scholar 

  23. 23.

    Steven C. Fluid Physiology and Pathology in Traditional Chinese Medicine. Churchill Livingstone; 1995. p. 154.

  24. 24.

    Philippe S, Lu G. The treatment of disease in TCM: general symptoms, vol. 7; 2000. p. 16.

    Google Scholar 

  25. 25.

    Li P, Zhang ZM, Li T, Zhang YB, Sze SC, Wang GC, Li YL, Ye WC. Monoterpene derivatives from the roots of Paeonia lactiflora and their anti-proliferative activity. Fitoterapia. 2014;98:124–9.

    CAS  Article  Google Scholar 

  26. 26.

    Wang YL, Tan X, Yang XL, Li XY, Bian K, Zhang DD. Total flavonoid from Glycyrrhizae Radix et Rhizoma and its ingredient isoliquiritigenin regulation M2 phenotype polarization of macrophages. Zhongguo Zhong Yao Za Zhi. 2015;40(22):4475–81.

    CAS  PubMed  Google Scholar 

  27. 27.

    Yu FR, Lian XZ, Guo HY, McGuire PM, Li RD, Wang R, Yu FH. Isolation and characterization of methyl esters and derivatives from Euphorbia kansui (Euphorbiaceae) and their inhibitory effects on the human SGC-7901 cells. J Pharm Pharm Sci. 2005;8:528–35.

    CAS  PubMed  Google Scholar 

  28. 28.

    Su T, Zhang WW, Zhang YM, Cheng BC, Fu XQ, Li T, Guo H, Li YX, Zhu PL, Cao H, Yu ZL. Standardization of the manufacturing procedure for Pinelliae Rhizoma Praeparatum cum Zingibere et Alumine. J Ethnopharmacol. 2016;193:663–9.

    CAS  Article  Google Scholar 

  29. 29.

    Rose NR, McDonough MA, King ON, Kawamura A, Schofield CJ. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev. 2011;40(8):4364–97.

    CAS  Article  Google Scholar 

  30. 30.

    Al-Qahtani K, Jabeen B, Sekirnik R, Riaz N, Claridge TDW, Schofield CJ, McCullagh JSO. The broad spectrum 2-oxoglutarate oxygenase inhibitor N-oxalylglycine is present in rhubarb and spinach leaves. Phytochemistry. 2015;117:456–61.

    CAS  Article  Google Scholar 

  31. 31.

    Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, Li L, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Liu S, Xie Y, Gadde S, Li X, Wang L. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death Dis. 2018;9:815.

    Article  Google Scholar 

  32. 32.

    Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J Cell Mol Med. 2018;22:1167–78.

    CAS  PubMed  Google Scholar 

  33. 33.

    Li J, Liu X, Chen H, Sun Z, Chen H, Wang L, Sun X, Li X. Multi-targeting chemoprevention of Chinese herb formula Yanghe Huayan decoction on experimentally induced mammary tumorigenesis. BMC Complement Altern Med. 2019;19:48.

    Article  Google Scholar 

  34. 34.

    Liu J, Wang S, Zhang Y, Fan HT, Lin HS. Traditional Chinese medicine and cancer: history, present situation, and development. Thorac Cancer. 2015;6:561–9.

    Article  Google Scholar 

  35. 35.

    Shen J, Kai J, Tang Y, Zhang L, Su S, Duan JA. The chemical and biological properties of Euphorbia kansui. Am J Chin Med. 2016;44:253–73.

    CAS  Article  Google Scholar 

  36. 36.

    Zheng WF, Cui Z, Zhu Q. Cytotoxicity and antiviral activity of the compounds from Euphorbia kansui. Planta Med. 1998;64:754–6.

    CAS  Article  Google Scholar 

  37. 37.

    Cheng F, Yang Y, Zhang L, Cao Y, Yao W, Tang Y, Ding A. A natural triterpene derivative from Euphorbia kansui inhibits cell proliferation and induces apoptosis against rat intestinal epithelioid cell line in vitro. Int J Mol Sci. 2015;16:18956–75.

    CAS  Article  Google Scholar 

  38. 38.

    Hu B, Zhang H, Meng X, Wang F, Wang P. Aloe-emodin from rhubarb (Rheum rhabarbarum) inhibits lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. J Ethnopharmacol. 2014;153:846–53.

    CAS  Article  Google Scholar 

  39. 39.

    Hu H, Zhu Q, Su J, Wu Y, Zhu Y, Wang Y, Fang H, Pang M, Li B, Chen S, Lv G. Effects of an enriched extract of Paeoniflorin, a monoterpene glycoside used in Chinese herbal medicine, on cholesterol metabolism in a Hyperlipidemic rat model. Med Sci Monit. 2017;23:3412–27.

    Article  Google Scholar 

  40. 40.

    Sun X, Li S, Xu L, Wang H, Ma Z, Fu Q, Qu R, Ma S. Paeoniflorin ameliorates cognitive dysfunction via regulating SOCS2/IRS-1 pathway in diabetic rats. Physiol Behav. 2017;174:162–9.

    CAS  Article  Google Scholar 

  41. 41.

    Wu JJ, Sun WY, Hu SS, Zhang S, Wei W. A standardized extract from Paeonia lactiflora and Astragalus membranaceus induces apoptosis and inhibits the proliferation, migration and invasion of human hepatoma cell lines. Int J Oncol. 2013;43:1643–51.

    Article  Google Scholar 

  42. 42.

    Wu Q, Chen GL, Li YJ, Chen Y, Lin FZ. Paeoniflorin inhibits macrophage- mediated lung cancer metastasis. Chin J Nat Med. 2015;13:925–32.

    CAS  PubMed  Google Scholar 

  43. 43.

    Li Y, Gong L, Qi R, Sun Q, Xia X, He H, Ren J, Zhu O, Zhuo D. Paeoniflorin suppresses pancreatic cancer cell growth by upregulating HTRA3 expression. Drug Des Devel Ther. 2017;11:2481–91.

    CAS  Article  Google Scholar 

  44. 44.

    Zhang ZH, Xie DD, Xu S, Xia MZ, Zhang ZQ, Geng H, Chen L, Wang DM, Wei W, Yu DX, Xu DX. Total glucosides of paeony inhibits lipopolysaccharide- induced proliferation, migration and invasion in androgen insensitive prostate cancer cells. PLoS One. 2017;12:e0182584.

    Article  Google Scholar 

  45. 45.

    Lv C, Shi C, Li L, Wen X, Xian CJ. Chinese herbal medicines in the prevention and treatment of chemotherapy-induced nausea and vomiting. Curr Opin Support Palliat Care. 2018;12:174–80.

    PubMed  Google Scholar 

  46. 46.

    Levy JM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther. 2011;131:130–41.

    CAS  Article  Google Scholar 

  47. 47.

    Maycotte P, Thorburn A. Autophagy and cancer therapy. Cancer Biol Ther. 2011;11:127–37.

    CAS  Article  Google Scholar 

  48. 48.

    Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 2014;65:139–55.

    CAS  Article  Google Scholar 

  49. 49.

    Fulda S. Targeting autophagy for the treatment of cancer. Biol Chem. 2018;399:673–7.

    CAS  Article  Google Scholar 

  50. 50.

    Kallunki T, Olsen OD, Jaattela M. Cancer-associated lysosomal changes: friends or foes? Oncogene. 2013;32:1995–2004.

    CAS  Article  Google Scholar 

  51. 51.

    Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.

    Article  Google Scholar 

  52. 52.

    Abdullah LN, Chow EKH. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2:3.

    Article  Google Scholar 

  53. 53.

    Jia D, Li L, Andrew S, Allan D, Li X, Lee J, Ji G, Yao Z, Gadde S, Figeys D, Wang L. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis. 2017;8:e2932.

    CAS  Article  Google Scholar 

  54. 54.

    Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lonborg A, Vindeløv SD, Hanahan D, Arenz C, Ejsing CS, Kirkegaard T, Rohde M, Nylandsted J, Jäättelä M. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013;24:379–93.

    CAS  Article  Google Scholar 

  55. 55.

    Ross DT, Perou CM. A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers. 2001;17:99–109.

    CAS  Article  Google Scholar 

  56. 56.

    Furth PA. STAT signaling in different breast cancer sub-types. Mol Cell Endocrinol. 2014;382:612–5.

    CAS  Article  Google Scholar 

  57. 57.

    Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother. 2015;16:983–98.

    CAS  Article  Google Scholar 

  58. 58.

    Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis. 2018;9:21.

    Article  Google Scholar 

  59. 59.

    Riobo-Del Galdo NA, Lara Montero Á, Wertheimer EV. Role of hedgehog signaling in breast cancer: pathogenesis and therapeutics. Cells. 2019;8:E375.

    Article  Google Scholar 

  60. 60.

    Cao W, Li J, Hao Q, Vadgama JV, Wu Y. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019;21:29.

    Article  Google Scholar 

  61. 61.

    Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50:33.

    Article  Google Scholar 

  62. 62.

    Zhou X, Seto SW, Chang D, Kiat H, Razmovski-Naumovski V, Chan K, Bensoussan A. Synergistic effects of Chinese herbal medicine: a comprehensive review of methodology and current research. Front Pharmacol. 2016;7:201.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not Applicable.

Funding

This study was supported by Grant 104-CSMU37 and 104-CSMU38 from Chung Shan Medical University, Taiwan. The funders of Grant 104-CSMU37 and 104-CSMU38 play no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author information

Affiliations

  1. Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, No. 110, Section 1, Jianguo N. Rd., Taichung, 402, Taiwan, Republic of China

    Yu-Te Liu, Chao-Hsiang Hsiao, Bor-Show Tzang & Tsai-Ching Hsu

  2. Clinical Laboratory, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China

    Bor-Show Tzang & Tsai-Ching Hsu

  3. Department of Biochemistry, School of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China

    Bor-Show Tzang

  4. Immunology Research Center, Chung Shan Medical University, Taichung, Taiwan, Republic of China

    Bor-Show Tzang & Tsai-Ching Hsu

Authors
  1. Yu-Te Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chao-Hsiang Hsiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bor-Show Tzang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsai-Ching Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceived and designed the study: YTL, BST, TCH. Performed the study: CHH, BST, TCH. Analyzed the data: CHH, BST, TCH. Wrote the paper: BST and TCH. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Bor-Show Tzang or Tsai-Ching Hsu.

Ethics declarations

Ethics approval and consent to participate

All animal treatment and experiments were approved by the Institutional Animal Care and Use Committee of Chung Shan Medical University, Taichung, Taiwan (IACUC approval number: 1743).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, YT., Hsiao, CH., Tzang, BS. et al. In vitro and in vivo effects of traditional Chinese medicine formula T33 in human breast cancer cells. BMC Complement Altern Med 19, 211 (2019). https://doi.org/10.1186/s12906-019-2630-5

Download citation

Keywords

  • Breast cancer
  • Traditional Chinese medicine (TCM)
  • MDA-MB231
  • MCF-7
  • Autophagy

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us